Sanofi

Who's the Frailest Big Pharma of All?

Who's the Frailest Big Pharma of All?

Motley Fool

Sanofi Gets EU Backing for New Attempt at 6-in-1 Child Vaccine

Sanofi Gets EU Backing for New Attempt at 6-in-1 Child Vaccine

Bloomberg

A Strong Growth Opportunity In Multiple Sclerosis

A Strong Growth Opportunity In Multiple Sclerosis

Motley Fool

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Yahoo

Biomarin: This Mid-Cap Pharmaceutical is a Prime Takeover Target

Biomarin: This Mid-Cap Pharmaceutical is a Prime Takeover Target

Motley Fool

Sanofi's Orphan Drug Eliglustat Tartrate Successful in 2 Late-Stage Trials

Sanofi's Orphan Drug Eliglustat Tartrate Successful in 2 Late-Stage Trials

Motley Fool

The Best Dividend in Big Pharma

The Best Dividend in Big Pharma

Motley Fool

Pfizer to Novartis Seen Gaining as Drought Ends: Health

Pfizer to Novartis Seen Gaining as Drought Ends: Health

Bloomberg

Regeneron shares jump on Sanofi share buy plan

Regeneron shares jump on Sanofi share buy plan

Marketwatch

Sanofi advances after FDA delays rival insulin product

Sanofi advances after FDA delays rival insulin product

The Fly on the Wall